Amgen takes 20% stake in Chinese biotech BeiGene for $2.7 billion – CNBC

Biotechnology company Amgen announced Thursday it is investing $2.7 billion in BeiGene, taking a 20.5% stake in the Chinese biotech firm, valuing it at roughly $13.5 billion.
Under the all-cash deal, Amgen will pay BeiGene shareholders $174.85 per share, a 2…

Click here to view the original article.